Related Experiment Video
Updated: May 31, 2026

09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients
Vincenzo Russo1, Francesca Lunghi, Raffaella Fontana
11. Cancer Gene Therapy Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy;
Journal of Cancer
|July 1, 2011
Abstract:
In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3(+) melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were assessed by in vitro assay and delayed-type hypersensitivity skin testing.

